Effectiveness of empagliflozin in reducing hypoglycemic events as compared to sulfonylurea in type 2 diabetes patients during fasting in Ramadan: a single-center study.

ABSTRACT:

Background

This study aimed to compare the reduction in hospital admissions due to hypoglycemia and the decrease in HbA1c levels between empagliflozin and sulfonylurea, alongside the standard care provided to patients with type 2 diabetes during fasting.

Methodology

A single-center prospective observational cohort study was conducted from March to June 2022. Patients were treated with stable doses of empagliflozin, sulfonylureas, metformin, and DPP-4 inhibitors at least two months before fasting. Stability was defined as unchanged doses for at least one month. Participants' BMI distribution and treatment regimens were clarified. The eGFR cutoff of < 60 ml/min/1.73 m² was chosen based on international standards for renal function in diabetes.

Results

Females were in th

SUBMITTER: Kiran Z 

PROVIDER: S-EPMC12849180 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature